Targets › MAPK3
5 programs from 4 companies in 7 trials: 4 Phase 1, 3 Phase 2; Oncology; next expected readout Dec 2026.
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. (UniProt, P27361)
Open in Phaseline: the race on MAPK3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Ulixertinib MAP kinase ERK1 inhibitor; MAP kinase ERK2 inhibitor | MAPK3, MAPK1 | Phase 2 | Advanced Lymphoma; Advanced Malignant Solid Neoplasm | Dec 2026 |
| Memorial Sloan Kettering Cancer Center | Ulixertinib MAP kinase ERK1 inhibitor; MAP kinase ERK2 inhibitor | MAPK3, MAPK1 | Phase 2 | Histiocytic Neoplasms; Myelofibrosis | May 2027 |
| UNC Lineberger Comprehensive Cancer Center | Ulixertinib MAP kinase ERK1 inhibitor; MAP kinase ERK2 inhibitor | MAPK3, MAPK1 | Phase 1 | Tumor, Solid | Feb 2028 |
| M.D. Anderson Cancer Center | Ulixertinib MAP kinase ERK1 inhibitor; MAP kinase ERK2 inhibitor | MAPK3, MAPK1 | Phase 1 | Metastatic Colorectal Cancer | Mar 2028 |
| M.D. Anderson Cancer Center | Temuterkib (LY3214996) Mitogen-activated protein kinase; ERK1/ERK2 inhibitor | MAPK3, MAPK1 | Phase 1 | Metastatic Colon Adenocarcinoma | Dec 2028 |
Histiocytic Neoplasms (1) Myelofibrosis (1) Metastatic Colon Adenocarcinoma (1) Metastatic Colorectal Cancer (1) Tumor, Solid (1) Advanced Lymphoma (1) Advanced Malignant Solid Neoplasm (1)
small molecule (3), mixed (2)
M.D. Anderson Cancer Center (2) Memorial Sloan Kettering Cancer Center (1) UNC Lineberger Comprehensive Cancer Center (1) National Cancer Institute (NCI) (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.